Intera Oncology

Intera Oncology is a private, commercial-stage medical device company advancing Hepatic Artery Infusion (HAI) therapy for liver-dominant metastatic cancers. The company's flagship product, the Intera 3000 HAI Pump, is an implantable device designed to deliver chemotherapy at significantly higher concentrations directly to liver tumors via the hepatic artery, aiming to improve efficacy and reduce systemic side effects. Founded by individuals personally impacted by these cancers, the company's mission is to expand access to HAI therapy, which is currently offered at a limited number of leading academic cancer centers. Intera Oncology operates in the oncology sector with a clear focus on a specific, high-need patient population.

The Intera 3000 Hepatic Artery Infusion (HAI) Pump, an implantable, programmable device for the localized, direct delivery of chemotherapy to liver tumors via the hepatic artery, achieving up to 400x higher drug concentration versus systemic administration.

Competition primarily comes from alternative liver-directed therapies such as radioembolization (Y-90), chemoembolization (TACE), and ablation, as well as from advancing systemic chemotherapy regimens, targeted therapies, and immunotherapies. Intera's HAI therapy competes by offering continuous, high-dose localized chemotherapy with a different efficacy and side-effect profile compared to these modalities.